NRX Pharmaceuticals
NRXP
20 hedge funds and large institutions have $44.7M invested in NRX Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 3 closing their positions.
2% more capital invested
Capital invested by funds: $44.1M → $44.7M (+$661K)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.02% less ownership
Funds ownership: 4.98% → 4.96% (-0.02%)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
+$1.24M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$595K |
| 3 |
CI
Cowen Inc
New York
|
+$320K |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$277K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIM
Longfellow Investment Management
Boston,
Massachusetts
|
-$972K |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$516K |
| 3 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$485K |
| 4 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$423K |
| 5 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
-$117K |
NRXP Hedge Fund Activity: Q4 2018 in Review
20 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q4 2018, worth a combined $44.7M — up 1.5% from $44.1M a quarter earlier.
Fund positioning in NRXP was balanced in Q4 2018: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 5 trimmed.
The largest buyer was Mizuho Securities USA, opening a new position worth an estimated $1.24M. The largest seller was Longfellow Investment Management, exiting entirely with an estimated $972K sold.
- 20 institutional investors held NRX Pharmaceuticals (NRXP) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $44.7M of NRX Pharmaceuticals stock for Q4 2018, up 1.5% quarter-over-quarter.
- 3 funds opened new NRX Pharmaceuticals positions in Q4 2018 and 3 closed out, a net change of 0 holders.
- The largest NRX Pharmaceuticals buyer in Q4 2018 was Mizuho Securities USA, an estimated $1.24M added.
- The largest NRX Pharmaceuticals seller in Q4 2018 was Longfellow Investment Management, an estimated $972K sold.
Based on aggregated 13F filings for Q4 2018.